One in 3 high blood pressure patients failing to take medication

One in three people who suffer from high blood pressure are failing to take medication as prescribed by their healthcare professionals, a new study led by the University of Leicester has suggested. A study on 1,400 hypertensive patients, conducted in collaboration between the Universities of Leicester (lead authors Dr Pankaj Gupta, Dr Prashanth Patel from the Department of Cardiovascular Sciences at the University of Leicester), Manchester (Prof M Tomazweski) and Czech Republic (Prof J Widimsky) has used a novel urine test to find that non-adherence to prescribed medications is around 30-40%.

Non-adherence to medications has been known since the time of Hippocrates and has been found to be one of the important reasons for the lack of blood pressure control in at least 50% of the patients in the study - despite the availability of good medicines.

Non-adherence leads to poorer cardiovascular outcomes and is thought to cost $100 billion to the US health economy.

A crucial reason for the lack of progress in improving adherence has been the previous lack of a clinically useful objective measure to show when people are not taking their prescribed medicine.

The research team has worked to develop a robust and reliable biochemical screening method to assess for non-adherence to antihypertensive medications in urine or blood using a technique called liquid chromatography-tandem mass spectrometry.

The team has set up a National Centre for Adherence Testing (NCAT, This email address is being protected from spambots. You need JavaScript enabled to view it.) at Leicester's Hospitals and receive samples from around 25 hypertension clinics across UK.

The study showed that more than 41.6% of the UK cohort and 31.5% of the Czech cohort were non-adherent to their anti-hypertensive medications.

Moreover 14.5% of the UK and 12% of the Czech cohort were not taking any medications. Crucially non-adherence was related to the number of prescribed medications with the risk increasing by >75% with each increase in medication and it was highest with diuretics.

As well as the above, younger patients and females were found to have an increased risk of non-adherence to prescribed medications.

Dr Gupta said: "Given the high prevalence of non-adherence, we should assess patients, particularly those on multiple antihypertensive medications or those who do not have an expected response to treatment"

Dr Patel said: "This is a simple, relatively inexpensive and a robust test. It and has anecdotally changed the management of hypertension in many centres who use the test."

The researchers hope to ascertain whether non-adherent patients, on follow up, improved their medication taking behaviour and if adherence testing led to an improvement in blood pressure.

Gupta P, Patel P, Štrauch B, Lai FY, Akbarov A, Marešová V, White CMJ, Petrák O, Gulsin GS, Patel V, Rosa J, Cole R, Zelinka T, Holaj R, Kinnell A, Smith PR, Thompson JR, Squire I, Widimský J Jr, Samani NJ, Williams B, Tomaszewski M.
Risk Factors for Nonadherence to Antihypertensive Treatment.
Hypertension. 2017 Jun;69(6):1113-1120. doi: 10.1161/HYPERTENSIONAHA.116.08729.

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

Boehringer Ingelheim and OSE Immunotherapeutics an…

Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...